SCHEMBL2979379

SCHEMBL2979379

NS(=O)(=O)c1nn2cc(-c3cc(-c4ccccc4)no3)nc2s1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.76
KMT2A Q03164 2/20 0.76
CA12 O43570 6/20 0.53
CA1 P00915 6/20 0.53
CA2 P00918 6/20 0.53
CA9 Q16790 6/20 0.53
PTGS2 P35354 2/20 0.51
F2RL3 Q96RI0 3/20 0.50
TP53 P04637 3/20 0.46
NPC1 O15118 7/20 0.45
RAB9A P51151 7/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
ALOX15 P16050 2/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
MAPT P10636 1/20 0.45
KDM4E B2RXH2 1/20 0.43
HSD17B10 Q99714 1/20 0.43
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2540289 0.87 MEN1 (1.00) MEN1KMT2ACA12CA1CA2
SCHEMBL2981652 0.85 MEN1 (0.97) MEN1KMT2ACA12CA1CA2
SCHEMBL13204703 0.84 MEN1 (0.95) MEN1KMT2ACA12CA1CA2
SCHEMBL2969028 0.80 MEN1 (0.81) MEN1KMT2ACA12CA1CA2
SCHEMBL2978970 0.80 MEN1 (0.81) MEN1KMT2ACA12CA1CA2
SCHEMBL2977195 0.79 MEN1 (0.74) MEN1KMT2ACA12CA1CA2
SCHEMBL2976269 0.78 KMT2A (0.66) MEN1KMT2ACA12CA1CA2
SCHEMBL2978494 0.78 F2RL3 (0.79) MEN1KMT2AF2RL3
SCHEMBL3810413 0.78 MEN1 (0.69) MEN1KMT2ACA12CA1CA2
SCHEMBL13204667 0.78 MEN1 (0.81) MEN1KMT2ACA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772260-B2 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS INC. (CA) 2010-08-10 US disclosed
US-7772260-B2 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS INC. (CA) 2010-08-10 US disclosed
US-7772260-B2 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS INC. (CA) 2010-08-10 US disclosed
US-7741349-B2 Imidazo[2, 1-b]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS INC. (CA) 2010-06-22 US disclosed
US-7741349-B2 Imidazo[2, 1-b]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS INC. (CA) 2010-06-22 US disclosed
US-7741349-B2 Imidazo[2, 1-b]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS INC. (CA) 2010-06-22 US disclosed
US-7714003-B2 Imidazo[2,1-b ]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS INC. (CA) 2010-05-11 US disclosed
US-7714003-B2 Imidazo[2,1-b ]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS INC. (CA) 2010-05-11 US disclosed
US-7714003-B2 Imidazo[2,1-b ]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS INC. (CA) 2010-05-11 US disclosed
US-7700635-B2 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS INC. (CA) 2010-04-20 US disclosed
US-20070112043-A1 Acylated and non-acylated imidazo[2,1-b]-1,3,4,-thiadiazole-2-sulfonamides, and uses thereof AEGERA THERAPEUTICS, INC. (CA) 2007-05-17 US disclosed
US-20070088059-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides PHARMASCIENCE INC. (CA) 2007-04-19 US disclosed
US-20070088059-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides PHARMASCIENCE INC. (CA) 2007-04-19 US disclosed
US-20070088059-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides PHARMASCIENCE INC. (CA) 2007-04-19 US disclosed
US-20070021416-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS, INC. (CA) 2007-01-25 US disclosed
US-20070021416-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS, INC. (CA) 2007-01-25 US disclosed
US-20070021416-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS, INC. (CA) 2007-01-25 US disclosed
US-20070021476-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides PHARMASCIENCE INC. (CA) 2007-01-25 US disclosed
US-20070021476-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides PHARMASCIENCE INC. (CA) 2007-01-25 US disclosed
US-20070021476-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides PHARMASCIENCE INC. (CA) 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112043-A1 Acylated and non-acylated imidazo[2,1-b]-1,3,4,-thiadiazole-2-sulfonamides, and uses thereof AADAC, NAT1, PMP22 MEN1 1818/4885KMT2A 415/4885CA12 2245/4885
US-20070021476-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides SMN1; SMN2, PMP22, BDNF MEN1 3572/4885KMT2A 3862/4885CA12 3878/4885
US-20070021416-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides SMN1; SMN2, PMP22, BDNF MEN1 3572/4885KMT2A 3862/4885CA12 3878/4885
US-20070088059-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides SMN1; SMN2, PMP22, BDNF MEN1 3572/4885KMT2A 3862/4885CA12 3878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.